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Table 1. Characteristics of the BIOSTAT population by Coronary Angiography Realization  










Age, years 2516 68.4 ± 12.0 69.1 ± 11.9 63.7 ± 11.6 <0.0001 
Male gender, n (%) 2516 1846 (73.4 %) 1621 (73.6 %) 225 (71.4 %) 0.40 
BMI, kg/m² 2478 27.9 ± 5.5 27.8 ± 5.4 28.2 ± 6.1 0.29 
Heart rate, bpm 2497 82.3 ± 21.4 81.6 ± 21.3 87.4 ± 21.4 <0.0001 
SBP, mmHg 2511 124.7 ± 21.9 124.6 ± 21.6 125.3 ± 23.8 0.63 
DBP, mmHg 2511 74.9 ± 13.4 74.7 ± 13.0 76.1 ± 15.8 0.079 
Pulmonary rales, n (%) 2445 1291 (52.8 %) 1101 (51.5 %) 190 (61.5 %) 0.001 
Peripheral edema, n (%) 2099 1256 (59.8 %) 1106 (59.9 %) 150 (59.3 %) 0.85 
Elevated JVP, n (%) 1753 554 (31.6 %) 479 (31.2 %) 75 (34.4 %) 0.34 
NYHA class III/IV, n (%) 2446 1522 (62.2 %) 1324 (61.8 %) 198 (65.1 %) 0.26 
Orthopnea, n (%) 2511 879 (35.0 %) 745 (33.9 %) 134 (42.5 %) 0.003 
LVEF, % 2243 31.0 ± 10.6 31.4 ± 10.7 28.7 ± 9.7 <0.0001 
Northern Europe, n (%) 2516 1200 (47.7%) 1035 (47.0 %) 165 (52.4 %) 0.075 
Inpatient visit, n (%) 2516 1694 (67.3 %) 1389 (63.1 %) 305 (96.8 %) <0.0001 
Heart failure hospitalization 
within the last year, n (%) 
2516 794 (31.6 %) 
751 (34.1 %) 43 (13.7 %) <0.0001 
HF etiology: Ischemic, n (%) 2516 1103 (43.8 %) 988 (44.9 %) 115 (36.5 %) 0.005 
HF etiology: Hypertensive, n (%)  254 (10.1 %) 225 (10.2 %) 29 (9.2 %) 
 HF etiology: Valvular, n (%)  190 (7.6 %) 169 (7.7 %) 21 (6.7 %) 
 HF etiology: Other/mixed, n (%)  969 (38.5 %) 819 (37.2 %) 150 (47.6 %) 
 Precipitating factors for index heart failure, n (%) 
Acute coronary syndrome, n (%) 1703 155 (9.1 %) 101 (6.9 %) 54 (23.1 %) <0.0001 
Non-compliance, n (%) 1702 304 (17.9 %) 274 (18.7 %) 30 (12.9 %) 0.032 
Atrial Fibrillation, n (%) 1703 770 (45.2 %) 691 (47.0 %) 79 (33.8 %) 0.0002 
Infection, n (%) 1703 224 (13.2 %) 199 (13.5 %) 25 (10.7 %) 0.23 
Uncontrolled hypertension, n (%) 1703 244 (14.3 %) 198 (13.5 %) 46 (19.7 %) 0.012 
Renal dysfunction, n (%) 1703 439 (25.8 %) 403 (27.4 %) 36 (15.4 %) <0.0001 
Other/mixed, n (%) 1703 287 (16.9 %) 228 (15.5 %) 59 (25.2 %) 0.0002 
Coronary stenosis, n (%) 312 122 (39.1%) 0 122 (39.1 %) NA 
Comorbidities 
Hypertension, n (%) 2516 1569 (62.4 %) 1381 (62.7 %) 188 (59.7 %) 0.29 
Atrial Fibrillation, n (%) 2516 1143 (45.4 %) 1044 (47.4 %) 99 (31.4 %) <0.0001 
Diabetes mellitus, n (%) 2516 819 (32.6 %) 717 (32.6 %) 102 (32.4 %) 0.94 
Never smoked, n (%) 2513 940 (37.4 %) 838 (38.1 %) 102 (32.5 %) <0.0001 
Past smoker, n (%)  1220 (48.5 %) 1083 (49.2 %) 137 (43.6 %)  
Current smoker, n (%)  353 (14.0 %) 278 (12.6 %) 75 (23.9 %)  
COPD, n (%) 2516    436 (17.3 %) 385 (17.5 %) 51 (16.2 %) 0.57 
Stroke, n (%) 2516 233 (9.3 %) 217 (9.9 %) 16 (5.1 %) 0.006 
Peripheral Artery Disease, n (%) 2516 273 (10.9 %) 245 (11.1 %) 28 (8.9 %) 0.23 
Device therapy, n (%) 2516 618 (24.6 %) 591 (26.9 %) 27 (8.6 %) <0.0001 
Laboratory values 
Hemoglobin, g/dL 2293 13.2 ± 1.9 13.1 ± 1.9 13.5 ± 1.9 0.0009 
eGFR, ml/min/1.73m2 2516 62.4 ± 23.2 61.5 ± 23.3 69.4 ± 21.7 <0.0001 
Urea, mmol/L 2083 11.4 (7.6 - 18.2) 11.8 (7.8 - 18.6) 8.9 (6.5 - 15.0) <0.0001 
Sodium, mmol/L 2327 139.1 ± 4.0 139.1 ± 4.1 139.2 ± 3.7 0.92 
Potassium, mmol/L 2324 4.3 ± 0.6 4.3 ± 0.6 4.2 ± 0.6 0.001 
Albumin, g/L 2361 32.4 ± 8.8 32.4 ± 8.9 32.2 ± 7.9 0.75 
Glucose, mmol/L 1894 7.2 ± 3.1 7.1 ± 3.1 7.3 ± 2.8 0.31 
ALAT, UI/L 1804 25.0 (17.0 - 38.0) 24.0 (16.0 - 36.0) 32.0 (21.0 - 48.5) <0.0001 
ASAT, UI/L 1598 25.0 (19.0 - 35.0) 25.0 (19.0 - 34.0) 29.0 (21.0 - 41.0) <0.0001 
Gamma-GT, UI/L 1151 55.0 (28.0 - 108.2) 55.0 (28.0 - 108.0) 56.0 (28.0 - 114.0) 0.055 
Total bilirubin, µmol/L 1381 14.0 (10.0 - 21.0) 15.0 (10.0 - 21.0) 11.6 (8.7 - 17.0) 0.43 
HDL, mmol/L 1166 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 0.32 
LDL, mmol/L 1103 2.6 ± 1.1 2.5 ± 1.0 2.8 ± 1.1 0.007 
Total cholesterol, mmol/L 1407 4.3 ± 1.3 4.2 ± 1.3 4.5 ± 1.3 0.037 
Triglycerides, mmol/L 1309 1.5 ± 1.0 1.5 ± 1.1 1.4 ± 1.0 0.74 
LogNT-pro BNP, ng/L 2174 3.0 ± 1.4 3.1 ± 1.4 2.9 ± 1.2 0.10 
Troponin I, pg/mL 2352 12.8 (6.8 - 27.9) 12.3 (6.7 - 25.6) 19.1 (8.1 - 36.0) <0.0001 
Medication 
PCI or CABG, n (%) 2516 842 (33.5 %) 774 (35.2 %) 68 (21.6 %) <0.0001 
Loop diuretic, n (%) 2516 2504 (99.5 %) 2193 (99.6 %) 311 (98.7 %) 0.081 
ACEi/ARB, n (%) 2516 1820 (72.3 %) 1574 (71.5 %) 246 (78.1 %) 0.015 
Beta-blocker, n (%) 2516 2093 (83.2 %) 1829 (83.1 %) 264 (83.8 %) 0.75 
MRA, n (%) 2516 1339 (53.2 %) 1178 (53.5 %) 161 (51.1 %) 0.42 
Digoxin, n (%) 2516 491 (19.5 %) 441 (20.0 %) 50 (15.9 %) 0.081 
Death or heart failure 
hospitalization, n (%) 2516 1017 (40.4 %) 932 (42.3 %) 85 (27.0 %) <0.0001 
Death, n (%) 2516 657 (26.1 %) 612 (27.8 %) 45 (14.3 %) <0.0001 
Heart failure hospitalization n (%) 2516 609 (24.2 %) 559 (25.4 %) 50 (15.9 %) 0.0002 
Legend: MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; JVP, jugular venous pressure; 
NYHA, New York Heart Association; H, hospitalization; HF, heart failure; eGFR, estimated glomerular filtration 
rate; ALAT/ASAT, alanine and aspartate aminotransferase levels; NT-pro BNP, n-terminal pro brain natriuretic 
peptide; COPD, chronic pulmonary obstructive disease; PCI or CABG, percutaneous coronary intervention or 
coronary artery bypass grafting; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
European regions were divided in Southern countries (Greece, Italy, Serbia, Slovenia, and France) vs. Northern 













Table 2. Logistic regression for the odds of performing a coronary angiography 




Inpatient visit (yes) 11.554 (4.636-28.794) <0.0001 
Acute coronary syndrome (yes) 3.117 (1.939-5.009) <0.0001 
Troponin I (>36 pg/mL) 1.603 (1.115-2.305) 0.011 
Age (per each decade less) 1.389 (1.202-1.605) <0.0001 
eGFR (per 10 ml/min/1.73m2 increase) 1.085 (1.000-1.177) 0.049 
Device Therapy (yes) 0.430 (0.254-0.727) 0.002 
Heart failure hospitalization within the last year (yes) 0.577 (0.371-0.897) 0.014 
Previous PCI or CABG (yes) 0.614 (0.413-0.912) 0.016 
Legend: CI, confidence interval; eGFR, estimated glomerular filtration rate; PCI or CABG, percutaneous coronary 








































Table 3. Logistic regression for the odds of having a coronary artery stenosis 
Variable Odds Ratio (95%CI) for Coronary 
Critical Stenosis 
P-value 
Ischemic Heart Failure (yes) 33.426 (16.439-67.967) <0.0001 
Troponin I (per 1 Log increase) 1.309 (1.032-1.661) 0.026 





























 Table 4. Prognostic assessment of coronary angiography and presence of critical stenosis 
Outcome Coronary angiography: unadjusted 
HR (95%CI)  
P-value Coronary angiography:  adjusted* 
HR (95%CI)  
P-value 
Death or HHF 0.568 (0.455-0.709) <0.0001 0.714 (0.571-0.893) ** 0.003 
HHF 0.564 (0.422-0.754) <0.0001 0.702 (0.525-0.940) 0.017 
Death 0.460 (0.340-0.623) <0.0001 0.586 (0.433-0.795) ** 0.001 
Outcome Coronary stenosis: unadjusted 
HR (95%CI)  
P-value Coronary stenosis:  adjusted* 
HR (95%CI)  
P-value 
Death or HHF 1.940 (1.261-2.985) 0.003 1.705 (1.103-2.635) 0.016 
HHF 1.583 (0.903-2.776) 0.109 1.465 (0.833-2.575) 0.185 
Death 2.716 (1.473-5.009) 0.001 2.089 (1.103-3.957) 0.024 
Legend: HR, hazard ratio; 95%CI, 95% confidence interval; HHF, hospitalization for heart failure. 
*model adjusted on age, gender, NT-pro BNP, hemoglobin, urea, HDL-cholesterol, serum sodium, serum creatinine, 
systolic blood pressure, use of beta-blockers, presence of peripheral edema, and hospitalization for heart failure in the 
year before inclusion – the BIOSTAT risk calculator (https://biostat-chf.shinyapps.io/calc/). 
P for interaction HF etiology*Coronary Angiography =0.007 for the primary outcome of death or HHF; P =0.004 for 
death; and non-significant for HHF, P =0.326. 
**HR (95%CI) results for Coronary Angiography adjusted on the above models plus Heart Failure Etiology 
(ischemic vs. other) plus the interaction between Heart Failure Etiology and Coronary Angiography: Death or HHF 
=0.553 (0.402-0.761), p <0.0001; Death =0.378 (0.235-0.609), p <0.0001. 
Further adjustment on the type of centre: 1) university hospital, 2) large non-academic centre, and 3) small centre, 
provided overlapping results to those presented in the table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
